Sage Therapeutics, Inc. Overview
Pro stress-test →Sage Therapeutics is a biopharmaceutical company focused on brain health medicines and disorders of the brain. The company develops and commercializes innovative treatments for psychiatric and neurological disorders, focusing on significant unmet medical needs such as major depressive disorder and postpartum depression.
Strategic Profile
Pro stress-test →The company has a robust balance sheet enabling continued development of its NMDA and GABAA platform, positioned for long-term growth as total sales are projected to reach approximately $400 million by 2028. The lead commercial product, Zurzuvae, partnered with Biogen, is expected to gain significant traction in the treatment of postpartum depression due to its rapid onset of action and concise treatment regimen.
Competitive Landscape
Pro stress-test →Sage operates in the psychiatric and neurological disorders treatment space, competing with larger pharmaceutical and biotechnology companies developing CNS medications. Key competitors include Biogen (Zurzuvae partner), Johnson & Johnson, Eli Lilly, and other CNS-focused developers, though Sage differentiates through its NMDA and GABAA receptor platforms.
Industry Context
Sage Therapeutics, Inc. operates in Biopharmaceuticals - Central Nervous System.
Key facts
Founded: 2010 · Headquarters: Cambridge, US · Employees: 487 · Revenue: $70.41M · Market cap: $545M